Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation [RNA-seq]
RNA-seq (gene expression) · human · 48 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 48 samples: 16 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutationNPJ breast cancer · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE310672_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1366924 and SRA study SRP647173. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 48 samples.
How we read this: 16 replicated groups read from 48 sample titles; they account for 48 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9305687 2D_WT_shGFP_E2_R50_001 2D_WT_shGFP_E2_R50
- GSM9305688 2D_WT_shGFP_E2_R50_002 2D_WT_shGFP_E2_R50
- GSM9305689 2D_WT_shGFP_E2_R50_003 2D_WT_shGFP_E2_R50
- GSM9305690 2D_WT_shGFP_E2_veh_001 2D_WT_shGFP_E2_veh
- GSM9305691 2D_WT_shGFP_E2_veh_002 2D_WT_shGFP_E2_veh
- GSM9305692 2D_WT_shGFP_E2_veh_003 2D_WT_shGFP_E2_veh
- GSM9305693 2D_WT_shGFP_veh_R50_001 2D_WT_shGFP_veh_R50
- GSM9305694 2D_WT_shGFP_veh_R50_002 2D_WT_shGFP_veh_R50
- GSM9305695 2D_WT_shGFP_veh_R50_003 2D_WT_shGFP_veh_R50
- GSM9305696 2D_WT_shGFP_veh_veh_001 2D_WT_shGFP_veh_veh
- GSM9305697 2D_WT_shGFP_veh_veh_002 2D_WT_shGFP_veh_veh
- GSM9305698 2D_WT_shGFP_veh_veh_003 2D_WT_shGFP_veh_veh
- GSM9305699 2D_WT_shPR_E2_veh_001 2D_WT_shPR_E2_veh
- GSM9305700 2D_WT_shPR_E2_veh_002 2D_WT_shPR_E2_veh
- GSM9305701 2D_WT_shPR_E2_veh_003 2D_WT_shPR_E2_veh
- GSM9305702 2D_WT_shPR_veh_veh_001 2D_WT_shPR_veh_veh
- GSM9305703 2D_WT_shPR_veh_veh_002 2D_WT_shPR_veh_veh
- GSM9305704 2D_WT_shPR_veh_veh_003 2D_WT_shPR_veh_veh
- GSM9305705 2D_YS_shGFP_E2_R50_001 2D_YS_shGFP_E2_R50
- GSM9305706 2D_YS_shGFP_E2_R50_002 2D_YS_shGFP_E2_R50
- GSM9305707 2D_YS_shGFP_E2_R50_003 2D_YS_shGFP_E2_R50
- GSM9305708 2D_YS_shGFP_E2_veh_001 2D_YS_shGFP_E2_veh
- GSM9305709 2D_YS_shGFP_E2_veh_002 2D_YS_shGFP_E2_veh
- GSM9305710 2D_YS_shGFP_E2_veh_003 2D_YS_shGFP_E2_veh
- GSM9305711 2D_YS_shGFP_veh_R50_001 2D_YS_shGFP_veh_R50
- GSM9305712 2D_YS_shGFP_veh_R50_002 2D_YS_shGFP_veh_R50
- GSM9305713 2D_YS_shGFP_veh_R50_003 2D_YS_shGFP_veh_R50
- GSM9305714 2D_YS_shGFP_veh_veh_001 2D_YS_shGFP_veh_veh
- GSM9305715 2D_YS_shGFP_veh_veh_002 2D_YS_shGFP_veh_veh
- GSM9305716 2D_YS_shGFP_veh_veh_003 2D_YS_shGFP_veh_veh
- GSM9305717 2D_YS_shPR_E2_veh_001 2D_YS_shPR_E2_veh
- GSM9305718 2D_YS_shPR_E2_veh_002 2D_YS_shPR_E2_veh
- GSM9305719 2D_YS_shPR_E2_veh_003 2D_YS_shPR_E2_veh
- GSM9305720 2D_YS_shPR_veh_veh_001 2D_YS_shPR_veh_veh
- GSM9305721 2D_YS_shPR_veh_veh_002 2D_YS_shPR_veh_veh
- GSM9305722 2D_YS_shPR_veh_veh_003 2D_YS_shPR_veh_veh
- GSM9305723 3D_WT_ER_shGFP_001 3D_WT_ER_shGFP
- GSM9305724 3D_WT_ER_shGFP_002 3D_WT_ER_shGFP
- GSM9305725 3D_WT_ER_shGFP_003 3D_WT_ER_shGFP
- GSM9305726 3D_WT_ER_shPR_001 3D_WT_ER_shP
+ 8 more — browse all 48 samples with per-sample file links →
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE266407 ESR1 fusions invoke breast cancer subtype-dependent enrichment of ligand independent oncogenic signatures and phenotypes [ChIP-seq] 14 samples shares esr1, phenotypes
- GSE283978 Maf1 cooperates with progesterone receptors to repress RNA polymerase III transcription of select tRNAs 54 samples shares progesterone, receptors
- GSE255767 MCF-7 ESR1 drug response 70 samples shares esr1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.